StreetInsider.com News Articles

Wolfe Research Downgrades Intellia Therapeutics (NTLA) to Underperform

Thu, 16 Jul 2026 02:21:37 -0400

Wolfe Research analyst Andy Chen downgraded Intellia Therapeutics (NASDAQ: NTLA) from Peerperform to Underperform with a price target of $9.00.

The analyst comments: “Hypothetically, if we write off nex-z, lonvo-z must support the company, we only see a fair value of $4/share on DCF and $6/share on 2.0x EV / peak sales. We'd have $4.5B cumulative revenue with lonvo-z (~$3.5B US) vs consensus $6.5B+. But assuming $2M net price per patient (recall 340B exposure would be high here), our numbers are already aggressively assuming nearly one-third of the HAE market would be cured by Intellia. We also cannot imagine pureplay lonvo-z

Wolfe Research Downgrades Intellia Therapeutics (NTLA) to Underperform

Thu, 16 Jul 2026 02:21:37 -0400

Wolfe Research analyst Andy Chen downgraded Intellia Therapeutics (NASDAQ: NTLA) from Peerperform to Underperform with a price target of $9.00.

Form 4 Intellia Therapeutics, For: Jul 01 Filed by: Dube Michael P

Mon, 06 Jul 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260706/26736440.html

Form 4 Intellia Therapeutics, For: Jul 01 Filed by: Dube Michael P

Mon, 06 Jul 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260706/26736440.html

Form 4 Intellia Therapeutics, For: Jul 02 Filed by: Dulac Edward J III

Mon, 06 Jul 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260706/26736427.html

Form 4 Intellia Therapeutics, For: Jul 02 Filed by: Dulac Edward J III

Mon, 06 Jul 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260706/26736427.html

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 06 Jul 2026 16:05:00 -0400

CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on July 1, 2026, it awarded inducement grants to thirteen new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 53,250 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 06 Jul 2026 16:05:00 -0400

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 06 Jul 2026 16:05:00 -0400

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 06 Jul 2026 16:05:00 -0400

Form 144 Intellia Therapeutics, Filed by: Dulac Edward J III

Thu, 02 Jul 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260702/26728538.html

Form 144 Intellia Therapeutics, Filed by: Dulac Edward J III

Thu, 02 Jul 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260702/26728538.html

Canaccord Reiterates Buy Rating on Intellia Therapeutics (NTLA)

Tue, 16 Jun 2026 06:37:55 -0400

Canaccord analyst Whitney Ijem reiterated a Buy rating and $49.00 price target on Intellia Therapeutics (NASDAQ: NTLA).

The analyst commented: "Over the weekend at EAACI (Istanbul, June 12-15), NTLA shared additional Phase 3 data from lonvo-z's HAELO study in HAE, which was also published in NEJM (article here). The co had previously shared topline data in April (our thoughts here and here, webcast here, presentation here), where it met its primary endpoint of reduction in monthly attacks and key secondary of % pts who are attack-free and therapy-free. New data included stat sig improvements in all other key secondary endpoints and

Form 8-K Intellia Therapeutics, For: Jun 13

Mon, 15 Jun 2026 08:52:00 -0400

si-local-file:///var/storage/secattach/20260615/26644869.html

Form 8-K Intellia Therapeutics, For: Jun 13

Mon, 15 Jun 2026 08:52:00 -0400

si-local-file:///var/storage/secattach/20260615/26644869.html

H.C. Wainwright Reiterates Buy Rating on Intellia Therapeutics (NTLA)

Mon, 15 Jun 2026 06:48:40 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $25.00 price target on Intellia Therapeutics (NASDAQ: NTLA).

The analyst commented: "In April, Intellia announced that HAELO had met its primary endpoint with an 87% reduction vs. placebo (0.26 vs 2.1 [p<0.0001]) in monthly HAE attacks, in addition to one key secondary endpoint, with 62% of lonvo-z treated patients attack- and treatment-free for the 6-month efficacy evaluation period vs. only 11% of placebo treated patients (p<0.0001). On June 13, Intellia released additional information on key secondary endpoints in a presentation at the EAACI Annual Congress and simultaneously published in the

Intellia Therapeutics (NTLA) Reiterated at Market Outperform by Citizens

Mon, 15 Jun 2026 05:41:04 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $30.00 price target on Intellia Therapeutics (NASDAQ: NTLA).

The analyst commented, "Intellia Therapeutics reported additional data from the HAELO Ph3 at EAACI, rounding out previous top-line lonvo-z data. We view single-patient non-responder data with significantly reduced disease burden as an additional proof of value. NTLA reported top-line data in late April and announced that the study met the primary endpoint (see our coverage here and here). We maintain our Market Outperform rating and $30 DCF-derived price target ahead of the BLA submission for lonvo-z

For an analyst ratings summary and ratings history

Intellia reports positive Phase 3 results for hereditary angioedema treatment

Sat, 13 Jun 2026 07:30:14 -0400

Intellia Therapeutics Inc. (NASDAQ: NTLA) presented additional positive results from its Phase 3 HAELO clinical trial of lonvoguran ziclumeran for hereditary angioedema at the European Academy of Allergy & Clinical Immunology Annual Congress. The results were simultaneously published in the New England Journal of Medicine.

The trial met its primary endpoint with an 87% reduction in mean monthly attacks in the lonvo-z arm versus placebo during weeks 5 to 28. Additionally, 62% of patients receiving lonvo-z were attack-free and therapy-free for the six-month evaluation period, compared to 11% in the placebo arm.